Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Privacy Policy

Thank you for visiting the Avalanche Biotechnologies website and for reviewing our privacy policy. The following statement explains our policy regarding personal information you may supply when visiting our website: Avalanche Biotechnologies does not sell, rent, or share information with any other organization. We do not transfer information for any promotional or marketing purposes, nor is that information shared with any third parties whatsoever. Our website contains links to other sites. We are not responsible for the privacy practices of these websites.

Avalanche Biotechnologies, Inc. Announced That it Has Been Awarded Two Grants from the National Eye Institute to Fund Pre-clinical Studies Related to its Novel AAV Variant Technology

October 1, 2012

The first grant, funded through the SBIR program with Dr. Thomas W. Chalberg as Principal Investigator, is geared toward pre-clinical development of anti-VEGF vectors for diabetic macular edema. The second grant investigates Avalanche’s delivery technology in animal models of glaucoma; this grant was funded through the STTR program and is being coordinated by Avalanche in collaboration with Cornell Weill Medical College, with Dr. Anna-Maria Demetriades as Principal Investigator... Read More

Read All Avalanche News

@Avalanchebio Twitter Feed

Connect with Avalanche Biotech on Twitter